Evidence map›Paper›PMID 36490367›Full record

ArticleAnalytical chemistry2022

Cov

Bart Van Puyvelde, Katleen Van Uytfanghe, Laurence Van Oudenhove, Ralf Gabriels, Tessa Van Royen, Arne Matthys, Morteza Razavi, Richard Yip, Terry Pearson, Nicolas Drouin and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Analytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. A Targeted LC-MRMMolecular & cellular proteomics : MCP · 2024
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 5 countries.

Bart Van PuyveldeProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-7368-1762
Katleen Van UytfangheLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
Laurence Van OudenhoveWaters Corporation, 2600 Antwerp, Belgium.
Ralf GabrielsVIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.ORCID 0000-0002-1679-1711
Tessa Van RoyenVIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.
Arne MatthysVIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.
Morteza RazaviSISCAPA Assay Technologies, Inc., Box 53309, Washington, DC 20009, United States.
Richard YipSISCAPA Assay Technologies, Inc., Box 53309, Washington, DC 20009, United States.
Terry PearsonSISCAPA Assay Technologies, Inc., Box 53309, Washington, DC 20009, United States.
Nicolas DrouinDivision of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, 2333 AL Leiden, The Netherlands.ORCID 0000-0003-1568-7944
Jan ClaereboudtWaters Corporation, 2600 Antwerp, Belgium.
Dominic FoleyWaters Corporation, Wilmslow SK9 4AX, United Kingdom.
Robert WardleWaters Corporation, Wilmslow SK9 4AX, United Kingdom.
Kevin WyndhamWaters Corporation, Wilmslow SK9 4AX, United Kingdom.
Thomas HankemeierDivision of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, 2333 AL Leiden, The Netherlands.ORCID 0000-0001-7871-2073
Donald JonesLeicester Cancer Research Centre, RKCSB, Cardiovascular Research Centre, Glenfield Hospital, University of Leicester, Leicester LE1 7RH, United Kingdom.ORCID 0000-0001-6583-870X
Xavier SaelensVIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.
Geert MartensAZ Delta Medical Laboratories, AZ Delta General Hospital, 8800 Roeselare, Belgium.
Christophe P StoveLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-7126-348X
Dieter DeforceProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.
Lennart MartensVIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.ORCID 0000-0003-4277-658X
Johannes P C VissersWaters Corporation, Wilmslow SK9 4AX, United Kingdom.ORCID 0000-0001-6283-8456
N Leigh AndersonSISCAPA Assay Technologies, Inc., Box 53309, Washington, DC 20009, United States.
Maarten DhaenensProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-9801-3509
Ghent University · BEWaters (United States) · USUniversity of Victoria · CALeiden University · NLAZ Delta · BEUniversity of Leicester · GB

Funding

Medical Research Council MC_PC_18054
6 · The paper itself

Abstract

The pandemic readiness toolbox needs to be extended, targeting different biomolecules, using orthogonal experimental set-ups. Here, we build on our Cov-MS effort using LC-MS, adding SISCAPA technology to enrich proteotypic peptides of the SARS-CoV-2 nucleocapsid (N) protein from trypsin-digested patient samples. The Cov

Indexed as

COVID-19SARS-CoV-2Clinical Laboratory TechniquesCOVID-19 TestingHumansMass SpectrometryPeptidesSensitivity and SpecificityPeptides

Identifiers

PMID36490367
PMCPMC9773173
OpenAlexW4312032573

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.